Brian E. Miller, Ph.D. Is Appointed TMRW SVP of Sales – 25+ Plus Veteran of the Fertility Industry Executive

March 5, 2021

Brian E. Miller, Ph.D. will be responsible for bringing TMRW‘s innovative technology to fertility clinics in the United States.

In addition, Brian will also be integral to the ongoing development of new products and services that will expand TMRW’s offerings, enabling fertility clinics to further enhance and automate their clinical lab operations.

A veteran of the fertility industry, Brian has over 25 years of experience at the nexus of science and technology, scaling fertility products and solutions and bringing them to market to improve patient care. Brian has an extensive background in biotech and pharma sales, medical affairs, medical practice operations, business development, government affairs, clinical laboratory and research, and alliance partner management. Brian has a profound understanding of the clinicians and patients who he works with, which has allowed him to foster deep and long-lasting relationships with his clients.

Brian joins TMRW from CooperSurgical, the fertility, genomics, and women’s health division of The Cooper Companies (NYSE: COO), where he led all fertility and genomic solutions and patient advocacy for North America.

Previously, Brian was Chief Commercial Officer at Recombine, a clinical genetic testing company specializing in carrier screening which was acquired by CooperSurgical in 2016. He also served as Chief Operating Officer at the Fertility Centers of New England.  Earlier in his career, Brian held multiple senior positions at EMD Serono, where he helped lead a medical affairs team and managed all U.S. strategic accounts for endocrinology and fertility sales.  At Organon, as a medical liaison, he supported the science and launch of new products through education.

Brian began his career as an andrologist at the Hospital of Central Connecticut, and advanced to Associate Director of Clinical Research and reproductive endocrinology and andrology lab supervisor. He completed a Ph.D. from the University of Connecticut.

Alan Murray, TMRW’s Founder and Co-CEO commented: “Brian is one of the best known and most respected executives in the fertility field. Over his two decade career, he has won the trust and admiration of the leading clinicians and innovators in not only the fertility space, but also the many key intersecting disciplines such as genetic testing and lab operations. We could not be more delighted by his arrival to further TMRW’s appeal to innovators in the fertility space.”

“TMRW is leading the way in developing how IVF will be practiced in the future,” said Brian. “The automation revolution TMRW is leading is already benefiting clinicians and patients alike. I’m excited to join a team of innovators, who, in a short period of time, took an extraordinary vision to bring safety to cryospecimen management and developed a game-changing technology solution that will become the community standard in IVF labs worldwide. I am thrilled to be part of the ongoing innovation which is TMRW’s future.”

Brian’s appointment comes on the heels of TMRW’s commercial launch in February 2021.

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.